PTEN expression in breast and endometrial cancer: correlations with steroid hormone receptor status - PubMed (original) (raw)
PTEN expression in breast and endometrial cancer: correlations with steroid hormone receptor status
H Kappes et al. Pathobiology. 2001.
Abstract
Objective: The PTEN (MMAC1/TEP1) tumor suppressor gene is frequently mutated and homozygously deleted in human neoplasms, but there is only sparse information about PTEN protein expression in hormone-dependent female tumors. Therefore, we investigated PTEN expression in 68 breast and 43 endometrial carcinomas.
Methods: For PTEN protein detection, we used Western blot analysis followed by densitometry and compared these data with clinicopathologic parameters, the estrogen receptor (ER) and progesterone receptor (PR) status, HER2/neu and the proliferation marker Ki67.
Results: We were able to show significantly decreased PTEN protein expression in endometrial carcinomas compared with normal endometrial tissue samples, especially in the endometrioid histological subtype. In contrast, PTEN downregulation was found more rarely in breast cancer. Lower PTEN expression in breast cancer correlated significantly with high ER immunoreactivity (p = 0.008) and was weakly associated with PR expression (p = 0.055) and low histological grading (p = 0.081). No correlation with any of these parameters was observed in endometrial tumors. In both tumor types, no association of PTEN expression with any other analyzed parameter was found.
Conclusions: These results suggest that PTEN expression plays different roles in the pathogenesis of endometrial carcinomas and breast cancer. In mammary carcinomas, loss of PTEN expression is mainly found in more differentiated tumors and is probably not a major event in carcinogenesis.
Copyright 2002 S. Karger AG, Basel
Similar articles
- PTEN immunohistochemical expression is suppressed in G1 endometrioid adenocarcinoma of the uterine corpus.
Kimura F, Watanabe J, Hata H, Fujisawa T, Kamata Y, Nishimura Y, Jobo T, Kuramoto H. Kimura F, et al. J Cancer Res Clin Oncol. 2004 Mar;130(3):161-8. doi: 10.1007/s00432-003-0517-8. Epub 2003 Dec 20. J Cancer Res Clin Oncol. 2004. PMID: 14689303 - Clinical implications and prognostic value of single and combined biomarkers in endometrial carcinoma.
Li M, Zhao L, Shen D, Li X, Wang J, Wei L. Li M, et al. Chin Med J (Engl). 2014;127(8):1459-63. Chin Med J (Engl). 2014. PMID: 24762589 - [Relationships between the molecular biomarkers and the clinicopathologic features and prognosis in endometrial carcinoma].
Yao YY, Xu WZ, Wang Y, Shen DH, Wang JL, Wei LH. Yao YY, et al. Beijing Da Xue Xue Bao Yi Xue Ban. 2011 Oct 18;43(5):743-8. Beijing Da Xue Xue Bao Yi Xue Ban. 2011. PMID: 22008688 Chinese. - HER-2/neu overexpression and hormone dependency in endometrial cancer: analysis of cohort and review of literature.
Mariani A, Sebo TJ, Katzmann JA, Riehle DL, Dowdy SC, Keeney GL, Lesnick TG, Podratz KC. Mariani A, et al. Anticancer Res. 2005 Jul-Aug;25(4):2921-7. Anticancer Res. 2005. PMID: 16080545 Review. - Prognostic role of hormone receptors in endometrial cancer: a systematic review and meta-analysis.
Zhang Y, Zhao D, Gong C, Zhang F, He J, Zhang W, Zhao Y, Sun J. Zhang Y, et al. World J Surg Oncol. 2015 Jun 25;13:208. doi: 10.1186/s12957-015-0619-1. World J Surg Oncol. 2015. PMID: 26108802 Free PMC article. Review.
Cited by
- Nuclear PTEN levels and G2 progression in melanoma cells.
Jacob AI, Romigh T, Waite KA, Eng C. Jacob AI, et al. Melanoma Res. 2009 Aug;19(4):203-10. doi: 10.1097/CMR.0b013e32832ccd6e. Melanoma Res. 2009. PMID: 19478684 Free PMC article. - Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response.
McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Montalto G, Cervello M, Nicoletti F, Fagone P, Malaponte G, Mazzarino MC, Candido S, Libra M, Bäsecke J, Mijatovic S, Maksimovic-Ivanic D, Milella M, Tafuri A, Cocco L, Evangelisti C, Chiarini F, Martelli AM. McCubrey JA, et al. Oncotarget. 2012 Sep;3(9):954-87. doi: 10.18632/oncotarget.652. Oncotarget. 2012. PMID: 23006971 Free PMC article. Review. - Somatic mutations are present in all members of the AKT family in endometrial carcinoma.
Dutt A, Salvesen HB, Greulich H, Sellers WR, Beroukhim R, Meyerson M. Dutt A, et al. Br J Cancer. 2009 Oct 6;101(7):1218-9; author reply 1220-1. doi: 10.1038/sj.bjc.6605301. Epub 2009 Sep 8. Br J Cancer. 2009. PMID: 19738612 Free PMC article. No abstract available. - Integrin αvβ3 in the Mediating Effects of Dihydrotestosterone and Resveratrol on Breast Cancer Cell Proliferation.
Ho Y, Li ZL, Shih YJ, Chen YR, Wang K, Whang-Peng J, Lin HY, Davis PJ. Ho Y, et al. Int J Mol Sci. 2020 Apr 21;21(8):2906. doi: 10.3390/ijms21082906. Int J Mol Sci. 2020. PMID: 32326308 Free PMC article. Review. - Triple-high expression of phosphatase and tensin homolog (PTEN), estrogen receptor (ER) and progesterone receptor (PR) may predict favorable prognosis for patients with Type I endometrial carcinoma.
Liang Y, Lin B, Ye Z, Chen S, Yu H, Chen C, Zhang X, Zhou K, Zeng J. Liang Y, et al. J Cancer. 2020 Jan 13;11(6):1436-1445. doi: 10.7150/jca.33720. eCollection 2020. J Cancer. 2020. PMID: 32047550 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous